PreprintAll rights reservedmedRxiv
Neuroplasticity-Based Treatment Prioritization in Major Depressive Disorder: A Two-Cohort Study
- 1NeuroKaire Inc
Related
- M1 neuroplasticity as a neurophysiological index of depressive symptom severity and treatment associated neural changes: a two-phase cross-sectional and randomized controlled trial
- Sex differences in the association between body mass index and recent suicide attempts in treatment-naïve young adults with major depressive disorder
- Peripheral immune biomarkers, brain imaging phenotypes and treatment response in major depressive disorder
- LSD treatment affects working memory-related brain function in patients with major depressive disorder
- Acylation Modifications at the Crossroads of Metabolism and Epigenetics: Unraveling the Neuroplasticity and Therapeutic Landscape of Depressive Disorders (Review).
BibTeX
@misc{solal2026neuroplasticitybased,
title = {{Neuroplasticity-Based Treatment Prioritization in Major Depressive Disorder: A Two-Cohort Study}},
author = {T. Cohen Solal and R. Amiaz and M. Maman and Z. Kassner and G. Keller and D. Ben Ami and M. Jaremko and E. Aloni and O. Goldman and M. Fava and D. Laifenfeld},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.06.26364759},
url = {https://www.medrxiv.org/content/10.64898/2026.10.06.26364759v1},
}
RIS
TY - UNPB
TI - Neuroplasticity-Based Treatment Prioritization in Major Depressive Disorder: A Two-Cohort Study
AU - T. Cohen Solal
AU - R. Amiaz
AU - M. Maman
AU - Z. Kassner
AU - G. Keller
AU - D. Ben Ami
AU - M. Jaremko
AU - E. Aloni
AU - O. Goldman
AU - M. Fava
AU - D. Laifenfeld
PY - 2026
DA - 2026/10/06
PB - medRxiv
DO - 10.64898/2026.10.06.26364759
UR - https://www.medrxiv.org/content/10.64898/2026.10.06.26364759v1
ER -